Resveratrol bioavailability and toxicity in humans.
Numerous data are now available on the beneficial properties of the polyphenolic compound resveratrol including its anti-inflammatory and antitumor effects. However, few studies have been performed with resveratrol in humans, and the results of these studies appear fragmentary and sometimes contradictory due to variations in conditions of administration, protocols and methods of assessment. This review article presents the results of recent studies investigating the pharmacokinetics, bioavailability, and toxicity of resveratrol in humans. Resveratrol is well absorbed, rapidly metabolized, mainly into sulfo and glucuronides conjugates which are eliminated in urine. Resveratrol seems to be well tolerated and no marked toxicity was reported. These data are important in the context of human efficacy studies, and they provide further support for the use of resveratrol as a pharmacological drug in human medicine.
Cottart
Charles-Henry
CH
APHP, Hôpital Universitaire Charles Foix, Service de Biochimie, Ivry sur Seine, France. charles-henry.cottart@parisdescartes.fr
Nivet-Antoine
Valérie
V
Laguillier-Morizot
Christelle
C
Beaudeux
Jean-Louis
JL
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000378:metabolism / Q000493:pharmacokinetics*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000378:metabolism / Q000493:pharmacokinetics*; D001682:Biological Availability; D001711:Biotransformation; D006801:Humans; D008517:Phytotherapy; D000077185:Resveratrol; D013267:Stilbenes / Q000009:adverse effects* / Q000378:metabolism / Q000493:pharmacokinetics*; D018675:Toxicity Tests
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000970:Antineoplastic Agents; D013267:Stilbenes; D000077185:Resveratrol